Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
MoonLake Immunotherapeutics - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
MLTX
Nasdaq
2836
www.moonlaketx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for MoonLake Immunotherapeutics
MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG
- Jan 10th, 2025 12:15 pm
MoonLake's Three New Trials Will Expand Sonelokimab's Potential, Wedbush Says
- Jan 8th, 2025 4:53 pm
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
- Jan 8th, 2025 12:00 pm
Is There An Opportunity With MoonLake Immunotherapeutics' (NASDAQ:MLTX) 27% Undervaluation?
- Jan 1st, 2025 11:09 am
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
- Nov 13th, 2024 1:00 pm
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update
- Nov 7th, 2024 12:00 pm
Biotechnology Value Fund L.P. Reduces Stake in MoonLake Immunotherapeutics
- Oct 9th, 2024 1:11 am
Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now?
- Sep 25th, 2024 3:55 am
MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock
- Sep 23rd, 2024 6:44 am
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
- Sep 9th, 2024 11:00 am
MoonLake Immunotherapeutics (MLTX): One of Oppenheimer’s Top Stock Picks For the Next 12 Months
- Aug 28th, 2024 12:21 am
We're Interested To See How MoonLake Immunotherapeutics (NASDAQ:MLTX) Uses Its Cash Hoard To Grow
- Aug 22nd, 2024 4:25 pm
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11
- Aug 7th, 2024 12:00 pm
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
- Jun 10th, 2024 12:00 pm
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
- May 16th, 2024 12:00 pm
MoonLake Immunotherapeutics Reports Q1 2024 Financial Outcomes
- May 8th, 2024 1:02 am
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
- May 7th, 2024 12:00 pm
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
- Apr 10th, 2024 11:00 am
MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business
- Mar 15th, 2024 3:36 pm
MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test
- Mar 11th, 2024 8:25 pm
Scroll